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Parkinson’s disease (PD) is a progressive neurodegenerative disorder afecting ~ 0.2 to 3.0% of the population. It 
is characterised by the core motor symptoms bradykinesia, resting tremor, rigidity, and postural  instability1,2. PD 
is also characterized by secondary non-motor symptoms such as hyposmia, constipation, orthostatic hypoten-
sion, depression, sleep disorders, decline in cognitive abilities, and deicits in visual processing. Many of these 
are present already at early stages of PD, whereas classical motor-related symptoms are present in the middle 
 stages3,4. he pathogenesis of PD develops during prodromal stages of the  disease5. Consequently, there is a high 
unmet need for validation of new biomarkers that can be used to assess new disease-modifying drug treatments 
in early or prodromal stages of  PD6.
According to the Braak staging hypothesis, PD is a progressive synucleinopathic disorder in which six disease 
stages are associated with a progressive pathology to neurological  structures7. Pathological hallmarks of PD are 
the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc)8 and Lewy bodies in addi-
tion to ‘Lewy neurites’: pathological inclusions of aggregated α-synuclein protein in  neurons9,10. Duplications 
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and triplications of the SNCA gene encoding the protein associated with autosomal dominant early onset PD are 
accompanied with post-mortem presentation of Lewy  bodies11 which suggests that changes in the homeostasis of 
the α-synuclein protein, i.e. increasing expression levels 30–50% can impact risk and onset of disease. α-synuclein 
found in Lewy bodies has oten undergone a posttranslational modiication e.g. phosphorylation at  Ser12912.
Changes in visual perception are common but oten overlooked in PD. Some of the most consistent deicits 
are changes in contrast  sensitivity13,14 and delays in visual evoked potentials (VEPs)15,16. he occurrence of these 
changes in PD have been linked to the spread of α-synuclein aggregates and to reductions of dopamine within 
the retinal amacrine  cells17,18.
In the adeno-associated virus (AAV) α-synuclein rat model of PD, protein expression and structural pathology 
originates from the injection site in the SNc, spreading to the striatal and cortical  regions19,20. In rodents, the SNc 
projects to the superior colliculus (SC)21, while indirect links exist between the SNc and visual cortex (VC)22. 
he SC is believed to be the most prominent retinal target in the rodent visual system, receiving ~ 90% of the 
projections from the retinal ganglion  cells23,24. hus, there is potential for changes in α-synuclein homeostasis to 
afect visual processing in a rodent model of PD. he function of the SC is less studied in humans, however, the 
projections from the SNc to the SC are believed to be involved in detecting salient visual  events21.
Recent research reported changes in visual processing using Drosophila models of PD, identifying increased 
contrast sensitivity as a visual biomarker in young Drosophila expressing a gain-of-function variant of the human 
leucine-rich repeat kinase 2 (LRRK2-G2019S) causing autosomal dominant PD in  humans25. In the ly, phar-
macological inhibition of LRRK2-G2019S fully rescued visual perturbations. his research has expanded to 
include sensitive machine learning classiication techniques that allow the investigation of subtle, but important 
diferences in visual  function26,27. Establishing the utility of machine learning techniques to identify new visual 
biomarkers in animal models of diseases is important, as these techniques can be used as a tool for testing new 
therapeutic drugs that aim to alter disease progression, and deine cross-species biomarkers that could be trans-
lated to the human  condition28.
Here, we investigated changes in visual processing caused by α-synuclein overexpression in a rodent model 
of PD, using electrophysiological measurements of VEP and steady-state visually evoked potentials (SSVEPs) 
recorded from the VC and SC. Previous work has established that overexpression of human α-synuclein in the 
SNc leads to changes in iring pattern in the subthalamic nucleus of the  rat19. Importantly, genetic and phar-
macological ablation of LRRK2 using PFE360 rescued α-synuclein mediated changes in  iring19. From this, 
we hypothesise that the overexpression of α -synuclein and concomitant changes in protein homeostasis will 
cause changes in the VEP waveform, and such changes are likely to be rescued by LRRK2 inhibition. Previously, 
machine learning classiiers have proved successful in classifying Drosophila PD models into their correct group 
based on subtle diferences in visual responses. Consequently, we aim to investigate whether we can similarly clas-
sify rodents into their correct group using SSVEP proiles in a sensitive support vector machine (SVM) classiier.

All animal experimentation was carried out in accordance with the European Communities Council Directive 
(86/609/EEC), and in accordance with Danish law on care of laboratory animals. he protocols were approved 
by the Danish Animal Experiments Inspectorate (Forsøgsdyrstilsynet) prior to the initiation of the study.
Ǥ 26 female Sprague–Dawley rats, weighing 225 g at arrival, were used 
in the study. hey were housed in Makrolon type IV cages with wood bedding, a transparent shelter, nesting 
material and wooden sticks, in rooms with a temperature of 22 ± 1.5 °C and a humidity of 55–65%. Food and 
water was provided ad  libitum. Rats were anesthetized using 2.0  ml/kg Hypnorm® in saline and midazolam 
(B.Braun, Melsungen, Germany) in a 2:1:1 relation (equivalent to fentanyl 157 µg/kg) and placed in a stereotaxic 
frame. Local anaesthetic (Marcain, 2.5 mg/ml bupivacaine, AstraZeneca, Albertslund, Denmark) was injected 
prior to incision. A small drill was used to make seven holes in total: above the SNc (AP: − 5.5, ML: + 2.0 DV: − 
7.2) of the let hemisphere for injection of the AAV vector. Electrodes were implanted bilaterally in the SC (AP: 
− 6.0, ML: ± 1.0, DV: − 3.5) and VC (AP: − 6.0, ML: ± 4.0). he reference electrode was placed at (AT: + 8.0, ML: 
− 2.0) and the ground electrode at (AP: − 2.0, ML: + 4.0).
Rats were randomly assigned into one of two groups, α-synuclein or null, 13 rats in each group. he 
α-synuclein group received an injection of AAV vector into the let SNc, whereas the null group received an 
injection of the empty AAV vector. Both groups received injections of 3.0 μl of viral particles (30 × 1010 GC) car-
rying the rAAV2/5 viral vector (Vector biolabs, Malvern, PA, USA) expressing human wildtype SNCA (hSNCA) 
with a chimeric promoter containing part cytomegalovirus and a part of the synthetic chicken β-actin promoter. 
he injection was carried out using a 32G Hamilton cannula with an injection rate of 0.2 μl/min. he right hemi-
sphere received no treatment. Electrodes with a 15 mm mounting screw (E363/20/2.4/S, PlasticsOne, VA, US) 
were inserted into the visual cortex, reference, and ground holes. Stranded electrodes (E363/3/Spc, PlasticsOne, 
VA, US) were placed in the SC. he electrode leads were gathered in a plastic pedestal (PlasticsOne, VA, US) 
as a chronic implant attached using dental cement RelyX™ Unicem (3 M, Denmark) and Fuji plus (GC, US).
he procedure for all rats was completed over 9 days. Norodyl (carprofen 5 mg/kg) (ScanVet, Fredensborg, 
Denmark) and Noromox prolongatum (amoxicillintrihydrat 150 mg/kg) (ScanVet, Fredensborg, Denmark) were 
administered during surgery and for ive days post-surgery. Following surgery, the rats were kept on a reversed 
12 h circadian cycle (lights on at 6:00 PM). Rats were let to recover and acclimate for 2 weeks.
Ǥ In the VEP experiment, rats were exposed to lashes of light presented at 1 Hz 
using ive wavelength conditions to investigate interactions between α-synuclein overexpression and wave-
length. he wavelengths were: red light (20 lx, 620–625 nm), green light (20 lx, 525–530 nm), blue light (20 lx, 
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455–460 nm), short-wave blue light (5 lx, 405 nm), and white light (20 lx, 400–700 nm). Each rat was presented 
with 400 repetitions of each wavelength condition of the VEP stimulus at each testing session. In the SSVEP 
experiments, rats were presented with lickering luminance stimuli that lickered with a continuous square wave 
at a frequency of 14 Hz, with each presentation run lasting 100 s. Again, the SSVEP stimulus had ive wavelength 
conditions, identical to those used to evoke VEPs. he duration of each lash was 10 ms and there was no light 
in the cage between lashes. Lux was measured using an LED luxmeter (Extech, MA, US) located in the bottom 
of the cage. Stimuli were controlled by Spike2 ver. 7.13 (RRID:SCR_000903) (Cambridge Electronic Design Ltd, 
UK) and were presented using 5,050 SMD LEDs positioned 60 cm above the bottom of the cage.
Ǥ Rats were placed in a Makrolon type IV cage of polycarbonate with wood 
bedding and a Plexiglas box (measuring 43.8 × 35 × 27.9 cm) placed on top of the Makrolon cage. he test cage 
was placed inside a larger Faraday cage. Recordings were performed during the dark phase. VEP and SSVEP 
recordings were made at eight time points throughout an 11-week period (see Figure S1), counted from the 
irst day of surgery at 3, 5, 6, 7, 8, 9, 10, and 11 weeks using Spike2 ver. 7.13 while the animals were awake 
and behaving. Electrophysiological signals were ampliied and iltered using a Brownlee ampliier model 410 
(Brownlee Precision, CA, US) at the following settings: low-pass ilter; 200 Hz, high-pass ilter; 1 Hz, sampling 
rate; 1,000 Hz.
Ǥ Eleven weeks ater the injection of AAV, the rats were tested for motor asymmetry induced 
by the injection of α-synuclein in the let SNc. his overexpression afects the striatum ipsilateral of the injection 
and reduces the use of the contralateral paws. Rats were placed in a transparent plastic cylinder, with one paw 
dyed red and the other dyed green. he animals were recorded for ive minutes using a video camera. he num-
ber of touches on the plastic was counted and the ratio of contralateral to total number of touches was computed. 
he results from the two groups of rats were compared using an unpaired t-test.
	 ? ? ?Ǥ PFE360 is a LRRK2 kinase inhibitor irst described in Baptista et al.29. he 
drug was synthesized at Lundbeck A/S (Valby, Denmark) and dissolved in 10% captisol titrated to pH > 2 
using 1 M methanesulphonic acid to a concentration of 3 mg/ml. he rats were administered perorally with a 
dosage corresponding to 7.5 mg/kg of PFE360. he dosing was carried out as a randomized cross-over study 
14–15 weeks ater the injection of the AAV vector. EEG recordings were initiated 1 h ater administration at the 
expected maximum brain concentration  (Cmax)
19.
ǦȽǦǤ Brains were divided into three parts for 
western blotting, assessment of compound concentration in the brain, and histological validation of electrode 
location. he rostral part containing the striatum was frozen and used for western blotting. he medial part from 
13 of the 26 rats (seven control animals and six from the α-synuclein group) was immersion ixed and the medial 
part from the remaining 13 rats (six control animals and seven from the α-synuclein group) were used for west-
ern blotting. he immersion ixed brain parts were used for immunohistochemistry (this is shown in Figure S6), 
as the medial region contains the SC. he cerebellum was used to determine the brain concentration of PFE360.
ȽǦǡ ? ? ?ǦȽǦǡȋ ? ?ȌǡȋȌǡǦȋ
 ?Ȍǡ
ȋȌǡ  ?   ?Ǧ ? ? ?Ǥhe procedure for tissue preparation and western blotting is 
described in detail in Andersen et al.19. In brief, tissue punches were taken from the striatum and the SC and 
were homogenized using a Precellys® lysing kit (Bertin Instruments, France) with CelLytic M bufer (Merck, 
Germany) and proteases. Protein was isolated and the concentration was determined with BCA Protein Assay 
(hermo Scientiic, MA, US). For SDS-PAGE and western blotting procedures, 2.5 µg of protein was added 
in each well. Proteins were transferred unto immobilon-FL PVDF membranes (Millipore, Billerica, US). he 
membranes were incubated over night at 4 °C with primary antibody: human wildtype α-synuclein (1:10,000; 
4B12; hermo scientiic, US), pSer129-α-synuclein (1:1,000; ab51253; RabMAbs®, Abcam,UK), STEP (1:1,000; 
23E5; Millipore, US), TH (1:2000; ab152; Abcam, UK) , GAT1 (1:500; ab426; Abcam, UK), NeuN (1:1,000; 
ab104225; Abcam, UK), LRRK2 (1:2000; N241A/34; NeuroMab, US), LRRK2-pS935 (1:1,000; [udd2 10(12)] 
ab133450; Abcam, UK). he antibodies were detected using a Licor Odyssey system (LI-COR Biosciences, NE, 
US) with luorescent secondary antibodies and a Chameleon™ duo pre-stained protein ladder (LI-COR Bio-
sciences, NE, US). Intensity values for the luorescence of the TH band were measured using the Licor Image 
Studio Ver. 3.1.4 (LI-COR Biosciences, NE, US).  STEP46 immunoreactivity (IR) on Western Blot membranes 
was used as a dissection and loading control for tissue punched from the striatum. he  STEP46 isoform encoded 
by the PTPN5 gene is highly enriched in cells of striatal origin as opposed to the  STEP61  isoform
30. In addition, 
by evaluating  STEP46 IR a qualitative measure for striatal excitotoxity associated with the AAV model was also 
 ensured31.
Ǥ To pilot the rationale of a VEP study in the AAV model of PD, immunohistochemistry was per-
formed on four perfusion ixed brains from a previous study of the AAV-model in our lab. he brains were extracted 
at week 10–11 ater injection, and cut in slices of 40 µm on a freeze microtome and placed in potassium phos-
phate bufered saline (KPBS). he tissue was quenched with hydrogen peroxide and washed in KPBS before being 
incubated with primary antibody hWT-α-synuclein (4B12) (hermo scientiic, US) in the concentration 1:1,000. 
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Tissue was then washed before being incubated with the secondary antibody (E0464, DAKO, Denmark) and 
exposed using a 3,3-diaminobenzidine-reaction.
	 ? ? ?Ǥ he animals were decapitated ater the inal recording ses-
sion, approximately 3 h ater the last PFE360 dosing. Blood and brain tissue from the cerebellum were sampled 
ater the inal EEG recordings to determine the peripheral and central exposure of PFE360. he procedure for 
sampling and determination of the PFE360 concentration is described in detail in Andersen et al.19.
Ǥ he peak amplitude and the latencies of the lash VEPs were extracted from the Spike2 wave-
form display. We deined the peak amplitude as the diference from baseline to peak, measured in millivolts 
(mV). he latency of the peaks was measured relative to the stimulus ofset. he SSVEP data was exported from 
Spike2 and further analysed in MATLAB 2018a (RRID:SCR_001622) (Mathworks, MA, US).
he latency and amplitude of each peak of the VEP waveform were extracted manually in Spike2, for each rat 
and wavelength condition. Grand averages were computed for each electrode over all 400 stimulus repetitions. 
Statistical analysis for the amplitude and latency of the VEP, and the data obtained from the cylinder test, was 
carried out using the RStudio interface for R ver. 3.4.2 (RRID:SCR_000432) (Rstudio, MA, US).
Individual ANOVAs were conducted for both VC and SC. his resulted in 24 separate comparisons which 
were corrected for multiple comparisons using false discovery rate. As the AAV injection was unilateral, the con-
tralateral hemisphere was considered an internal control. his means that an efect of AAV-mediated α-synuclein 
overexpression on visual processing would be apparent as an interaction between the treatment group and the 
side in which the recording was made. he three-way ANOVAs included the variables side, group, and colour. 
he principles of the backward variable elimination strategy was applied to assess whether any of the variables 
could be  discarded32. Post-hoc comparisons were carried out using the Tukey multiple comparison test.
For the PFE360 experiments, a four-way ANOVA was applied with drug as an additional factor. he analysis 
was carried out using the backward variable elimination strategy, followed by Tukey post-hoc comparisons if 
p < 0.05.
 Ǥ SSVEPs are phase-locked electrophysiological signals that are traditionally analysed in 
the frequency domain, rather than the time  domain33. SSVEP data were analysed separately at each week using 
MATLAB 2018a (RRID:SCR_001622) (Mathworks, MA, USA). he data was comprised of 100 1 s bins. Figure S 
2A shows an example of an averaged EEG time course across 1 s. he irst 5 s and the last 5 s of each SSVEP time 
course was excluded to account for onset transients and ofset artefacts, thus retaining 90 1 s bins of EEG data 
per rat for each electrode and wavelength, at each week. hese data were transformed into the power spectrum 
by running a fast Fourier transform (FFT) on each 1 s bin. As presented in Figure S2B, amplitude peaks occurred 
at multiples of our input frequency, namely 1f (14 Hz) and 2f (28 Hz). We retained the Fourier amplitudes from 
these two frequencies as our frequencies of interest.
To ilter the data, the mean noise was computed by averaging the amplitudes in the four frequency bins 
above and below the two frequencies of interest (14 Hz and 28 Hz). To create a signal to noise (SNR) estimate, 
we compared the Fourier amplitude at 1f and 2f to the root mean square of the noise calculated from these local 
side bins. Any amplitude bins that had an SNR lower than 1 were excluded. hus, all amplitudes retained for 
further analysis had a Fourier amplitude that was larger than the average noise across the neighbouring bins of 
1f and 2f on the power spectrum.
he SNR measurements were used to minimize the variation contributed by noise in the SSVEP. We used a 
three-way ANOVA to test the α-synuclein induced diferences in SSVEPs within week 11. he variables were 
side, group, and colour.
Phase data were analysed using the CircStat toolbox for  Matlab34. A hktest (two-factor ANOVA, directional 
statistics)35 was computed for the pooled wavelength conditions. he independent variables were group and side.
ƤǤ he goal of using the SVM classiier was to accu-
rately classify rats based on multiple features of the SSVEP amplitude drawn from diferent electrode conigura-
tions. Each rat had a total of 40 potential SSVEP amplitude features that could be used in the classiication (i.e. 
amplitudes from 5 illumination wavelengths, 2 harmonics, and 4 electrodes) with 90 1 s bins of data for each 
feature. It is possible to apply a machine learning classiier to the two groups of rats and compute an overall 
classiication accuracy. However, this can lead to issues of overitting. To circumvent this, the classiication pro-
cedure was bootstrapped to perform multiple classiication iterations on groups of `synthetic’ rats by sampling 
data from the group-level population.
he classiication estimates were bootstrapped by repeatedly sampling (without replacement) from the 1 s bin 
pool of Fourier amplitudes. For each of the four electrodes, this sampling pool contained a maximum of 1,170 
Fourier amplitude bins (13 rats × 90 1 s bins). Wavelength was included as a feature, rather than classifying into 
wavelength, as an increase in features oten beneits classiication accuracy. We randomly permutated through 
these amplitude bins, assigning 90 random 1 s bins from each feature to each synthetic rat. hese 90 1 s bins 
were then averaged together for each feature. he phase data was not included in the SVM, as the summation of 
phase response across individual 1 s SSVEP bins may yield inaccurate phase information.
his created 13 synthetic α-synuclein rats and 13 synthetic control rats. Amplitude responses were normalized 
by Z-scoring the data across each synthetic rat. he Z-score of each feature was entered into the SVM classiier 
and labelled with the class that the data corresponded to; α-synuclein or control rat. Unique variations of these 
synthetic rats were run through 1,000 bootstrapped iterations of the SVM classiier to derive a mean classiica-
tion accuracy and corresponding signiicance value. he mean classiication accuracy was deemed signiicant 
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if less than 5% of the 1,000 iterations fell below a 50% chance baseline, equivalent to a p-value of 0.05. In an 
additional analysis, we shuled our rat labels on each run. If the SVM is working correctly, we would expect the 
mean classiication accuracy of shuled data to fall around chance (50%).
Ǥ he SVM is a robust supervised learning model based on statistical learning 
theory developed and irst implemented by Vladimir  Vapnik36. he SVM uses a non-linear hyperplane as clas-
siication boundary to assign new examples of data to either class, with the output being the accuracy of the 
SVM in classifying new examples of  data37–39. We bootstrapped a SVM classiication analysis in MATLAB 2018a 
using LIBSVM, ver. 3.2340. he SVM had a radial basis kernel function and a 5-sample k-fold cross validation, 
with four groups of data used as the training data and a single group used as the validation data for each run to 
avoid overitting.

ǦȽǦǤ To investigate the extent of spreading of the α-synuclein 
protein to the visual regions in the rats, the brains from rats injected with the AAV-hSNCA vector were collected 
at week 10–11 and stained for human wild-type α-synuclein (Fig. 1). All brains (n = 4) showed an abundance 
of α-synuclein expression in the ipsilateral SNc and surrounding areas, exclusively ipsilateral to the injection. 
Immunoreactivity towards human α-synuclein was also observed in the ipsilateral SC. No α-synuclein immuno-
reactivity was detectable in the contralateral hemisphere, although minor unspeciic binding around the edges 
of the tissue was observed.
ȽǦ       Ƥ   ȽǦ Ǥ he 
rats completed the cylinder test in week 11 to assess motor asymmetries associated with the behavioural conse-
quences of α-synuclein overexpression. he cylinder test (Figure S3A) showed a signiicant motor asymmetry in 
the group overexpressing α-synuclein, but not in the control group. here was a statistical signiicant diference 
in the mean ratio of contralateral touches to total number of touches (t(21) =  − 3.99, p < 0.001). he mean ratio 
Figure 1.  Detection of human α-synuclein immunoreactivity (IR) in the superior colliculus of rats injected 
with AAV- α-synuclein. (A–D) Images of immersion ixed brain slice stained with the 4B12 antibody for 
human wild-type α-synuclein and magniied 10 × and 40 × . (A) Human wt α-synuclein IR in the substantia 
nigra pars compacta (SNc). (C) A subsection of the human α-synuclein IR in the SNc at 40 × magniication. 
he magniication highlights cell bodies containing human wt α-synuclein. (B–D) Human wt α-synuclein IR 
appearing in the intermediate gray layer of the superior colliculus (SC).
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for the α-synuclein rats was 0.34 indicating that 34% of touches were with the paw contralateral to the side of 
injection (i.e. right paw). he control group used the two front paws equally, with a mean ratio of 0.49.
Further, as the immunohistochemistry was carried out on brains from a diferent study (see methods), west-
ern blotting was applied to validate the presence of exogenous human α-synuclein in the striatum and SC of the 
animals used in the present study. For a representative blot, see (Figure S3B and C). he western blots indicated 
that in the α-synuclein rats, α-synuclein was present in the SC and striatum ipsilateral to the injection. Contrary 
to this pSer129-α-synuclein was detected using WB with samples from the striatum of both the control and the 
α-synuclein rats, further pSer129-α-synuclein could only be detected around the injection site using immunohis-
tochemistry (Figure S6). STEP46 was used as a loading control and TH was quantiied in the striatum as ratio of 
contralateral to ipsilateral to the injection. here was no asymmetry induced by expressing human α-synuclein 
(t(7) =  − 1.57, p = 0.16) (Figure S4).
Ǥ Visual cortex is not impacted by AAV‑mediated α‑synuclein overexpression. Next, 
we investigated whether the overexpression of α-synuclein caused changes in the VEP measured from the VC. 
Figure 2A shows the grand average waveforms recorded from the right and the let VC in the AAV α-synuclein 
group at week 11. here was no signiicant diference in the amplitude or the latency of the VEP, when compar-
ing between VC of the two hemispheres of α-synuclein and control rats. his inding is corroborated by histo-
logical indings where no evidence of α-synuclein inclusions were present in either hemisphere of the VC (data 
not shown).
α‑synuclein alters VEP responses in the let SC. To investigate whether the overexpression of α-synuclein 
induced changes in visual processing we tested for diferences between ipsi- and contralateral sides using the 
latency and amplitude data of the rodent VEP by running a three-way ANOVA using the data from week 11 
(the inal week of testing). he grand average of the waveform is shown in Fig. 2B. he wavelength variable 
was eliminated as it did not interact with the expression of α-synuclein. here was a signiicant efect of the 
interaction between side and group on the latency of P1 measured in the SC (F(1,24) = 12.32, p = 0.002). he 
post-hoc comparisons revealed a 0.004 s mean latency increase for the let (α-synuclein expressing) SC (0.004 s, 
SE = 0.0013, p = 0.012) when compared to the right SC in the α-synuclein group. Similarly, there was a signiicant 
increase in latency (0.003 s, SE: 0.0013, p = 0.019) when comparing let SC in the α-synuclein rats and the control 
rats. here was no signiicant diference in latency between the right SC of α-synuclein group and control group 
(− 0.0019 s, SE = 0.0013, p = 0.44). hese indings suggest that the VEP obtained from the side of the injection 
in the α-synuclein animals is functionally afected, congruent with our histological inspections and results from 
the cylinder test.
Next, we investigated whether the diference in response latency was evident at the earliest stage in the 
model. Figure 2C shows that the diference in latency between the right and let hemisphere increases over 
time in the α-synuclein rats. his is not observed in the control rats. A three-way ANOVA on the efect of side 
group and colour did not show a signiicant interaction of side and group on the latency of P1 in week three 
(w3) (F(1,24) = 2.78, p = 0.11). his suggests that the increase in latency developed over time in parallel with the 
increase in expression of human α-synuclein. hese results indicate that the VEP waveform is sensitive to the 
overexpression of α-synuclein at the later stages in the model, as evidenced by increases in the latency of P1 in 
the let SC of the α-synuclein injected rats.
Modulation of the VEP by the LRRK2 inhibitor PFE360. In preclinical PD models, LRRK2 inhibition has been 
shown to normalize visual processing deicits in LRRK2-G2019S transgenic fruit  lies25 and normalize increases 
in burst iring of the subthalamic nucleus in AAV α-synuclein  rats19. Here, we investigate whether LRRK2 inhi-
bition can rescue the phenotype caused by overexpression of α-synuclein at week 14–15 ater injection. Fig-
ures 3A, B show the VEP waveforms (superimposed) of the grand averages from the four experimental groups: 
α-synuclein rats treated with either PFE360 or vehicle, and control rats treated with either PFE360 or vehicle. 
An increase in the latency of the waveforms was evident in both the SC and the VC in rats dosed with PFE360. 
Figure 3C shows the unbound concentration of PFE360 measured in the cerebellum ater electrophysiological 
recordings. he mean unbound concentration of PFE360 was 103 ± 46 nM (mean ± SD, n = 11). One rat sacri-
iced 3 hr ater acute administration of PFE360 had a free unbound brain concentration of 40 nM; signiicantly 
higher than the in vivo, IC50 of 2.3 nM (Andersen et al., 2018). his suggests that the LRRK2 kinase was inhib-
ited throughout the recording sessions. Further, western blotting conirmed that, the inhibition caused a subse-
quent reduction of phosphorylated LRRK2-pSer935 (Fig. S6, in supplementary material).
Running a 4-way ANOVA with the backward elimination of variables  method32 replicated the interaction 
between group and side from the irst study, showing a 3 ms increase in the latency of the P1 in the SC (Supple-
mental Table S1). Further, signiicant increases in mean latency of the N1 and N2 peaks of the VEP were observed 
with diferences of mean of 6 ms, and 10 ms, respectively. here was no signiicant diference in the P2 and P3 
peaks between the SC ipsi- and contralateral to the injection (data not shown). here was a signiicant three-way 
interaction of PFE360, wavelength, and group on the latency of P4 of the VC, and this peak was excluded from 
the visualization (Fig. 4). A signiicant additive efect of the PFE360 on the latency was observed for all other 
peaks in both the VC and the SC, but there was no detectable interaction between PFE360 and the α-synuclein 
overexpression (Supplemental Table S1). Finally, the latency of the peaks increased following PFE360 adminis-
tration (Fig. 4). All peaks are shown in the same graph to illustrate the consistency of the observed efect. his 
suggests that a single acute dose of PFE360 has an impact on the rat visual response that is independent of any 
changes introduced by the overexpression of α-synuclein.
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SSVEP shows an efect in the SNR of the irst harmonic. Following the VEP indings, we tested for efects of 
the α-synuclein overexpression in the SSVEP data at week 11. he signal-to-noise ratio (SNR) of the amplitude 
data from the irst harmonic of the VC showed a signiicant interaction of side and group (three-way ANOVA, 
F(1,244) = 6.84, p = 0.009), however post hoc comparisons found no signiicant diferences. In the SC, there was 
a signiicant efect of side in the irst harmonic (three-way ANOVA, F(1,244) = 4.60, p = 0.033), but no signiicant 
interaction of side and group. here were no signiicant diferences for the second harmonic. he phase data 
from the SC showed no signiicant interaction of side and group in either harmonic and there was no signiicant 
diference in phase response from the VC when comparing between α-synuclein rats and control rats.
SVM can accurately classify α‑synuclein rats vs. control rats. Currently, the SVM is considered to be one of the 
most eicient methods of classiication in real world applications. By applying the SVM we can ind the hyper-
plane that best separates α-synuclein and control data. To test the ability of the SVM to accurately classify difer-
Figure 2.  Unilateral α-synuclein overexpression in the SC causes a delay of the irst positive peak (P1) of the 
VEP. (A) he grand average VEP waveforms from the visual cortex recorded ipsilateral (black) and contralateral 
(grey) to the injection of AAV-α-synuclein at week 11 (averaged across colour). (B) he grand average VEP 
waveform from the SC (averaged across colour) recorded from animals expressing α-synuclein in the let 
substantia nigra ipsilateral (black) and contralateral (grey) to the injection of AAV-α-synuclein at week 11 
(averaged across colour). he peak around time 0 is an electrical artefact from the onset/ofset of the VEP 
stimulus. (C) Latency of the P1 peak from the waveform recorded from the SC shown as mean ± SEM at week 
3 and week 11 for both α-synuclein and control animals. he P1 recorded ipsilateral to the AAV-α-synuclein 
injection is signiicantly delayed at week 11 compared to P1 recorded contralateral to the injection. * p < 0.05.
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ences in visual processing, visual responses from the α-synuclein rat and control rat groups were compared, with 
amplitude data from all four electrodes included as features. he ability to distinguish between these two groups 
suggests signiicant variation in the SSVEP of these groups across the visual system. he average classiication 
accuracy of 1,000 bootstrapped runs from each week and corresponding signiicance values are presented in 
(Table 1) and histograms of these bootstrapped accuracies are visualized (Fig. 5). he SVM was highly accurate 
in classifying rats into their respective groups at each week, with classiications consistently reaching > 83% accu-
racy. he SVM was tested with shuled labels and found that average classiication accuracies fell around 50% 
across all weeks (illustrated by the dotted line in Fig. 5). his was similar for both analyses, indicating that the 
SVM was working as expected. Shuled label classiication accuracies and p values are available in (Table S2).
SVM can accurately classify SSVEP responses from let and right SC. Next, we assessed the ability of the SVM 
classiier in distinguishing between response amplitudes within the α-synuclein rats when only responses from 
the let (injected) and right (uninjected) SC were included in the analysis. he ability to distinguish between 
these two groups suggests signiicant variations in the SSVEP solely due to the expression of human wildtype 
α-synuclein. he average classiication accuracy of 1,000 bootstrapped runs at each week and corresponding 
p-values are presented in (Table 2) and histograms of these bootstrapped accuracies (and shuled accuracies) 
are visualized in (Fig. 6). Using SSVEP recordings from the α-synuclein group alone, the SVM was able to accu-
Figure 3.  PFE360-mediated LRRK2 inhibition throughout the recording session. (A) shows four superimposed 
VEP waveforms recorded from the VC of rats injected with either AAV-α-synuclein (solid lines) or the empty 
AAV vector (dashed lines). Following this, they were treated with either vehicle (black) or the LRRK2 inhibitor 
PFE360 (grey). (B) Four superimposed VEP waveforms recorded from the SC. (C) Free concentration of 
PFE360 measured in the cerebellum of the rats, n = 11, 2–4.5 h ater PFE360 administration. X-axis shows time 
since administration in hours. he broken line indicates the mean concentration.
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rately classify between SSVEPs recorded from the let and right SC at all weeks, except at week 10, although this 
was closely approaching statistical signiicance. Notably, the SVM performed better when all electrodes were 
included in the analysis, rather than just the electrodes from the SC of the α-synuclein group.
To sum up, these indings suggest that the SVM can accurately classify SSVEP responses in both α-synuclein 
rats and control rats across diferent electrode conigurations. hese results difer from our VEP results due to 
the highly sensitive nature of the SVM that can pick up nuanced diferences in visual response proiles. Overall, 
it appears that the SSVEP is sensitive to the presence of the PD-associated gene product from early α-synuclein 
expression at week 3, through to the fully developed overexpression at week 11.

he purpose of this study was to investigate the potential of using VEP and SSVEP responses to detect changes 
in α-synuclein homeostasis in a rodent model of PD. First, in the α-synuclein rats, α-synuclein and pSer129 
immunoreactivity was localized around the site of injection (the let SNc). Second, overexpression of α-synuclein 
was accompanied by an increase in the latency of the VEP measured from the ipsilateral SC, ater α-synuclein 
expression was fully developed. hird, inhibition of LRRK2 using PFE360 could not rescue the increase in 
latency, but instead caused general increases in the latency of the VEP waveform. Fourth, the SVM was able to 
accurately classify rats according to their presence or absence of α-synuclein overexpression across time using 
two diferent electrode conigurations.
Figure 4.  PFE360 causes an increase in the latency of VEP waveforms. All peaks are stacked to show the 
increase VEP latency. (A) Latency of each peak from the VEP recorded in the VC ater administration of either 
vehicle or PFE360. here was signiicant increase in latency for all peaks except the P4 in both groups. he P4 
peak from the VC was excluded as there was a statistically signiicant interaction of PFE360, wavelength, and 
group. (B) Latency of each peak from the VEP recorded from the SC ater administration of either vehicle 
or PFE360. here was a statistically signiicant increase in latency for all peaks. Mean ± SEM, all diferences 
between vehicle and PFE360 condition were signiicant with p values < 0.001 (see Table S1).
Table 1.  Mean SVM classiication accuracy at each age ater 1,000 bootstrapped runs, classifying α-synuclein 
rats and control rats into their correct class, when all electrodes were included in the analysis. **p < 0.001, 
*p < 0.05.
Week Accuracy (%) p-value
3 83.71** p < .001
5 87.98** p < .001
6 92.28** p < .001
7 88.99** p < .001
8 86.79** p < .001
9 90.16** p < .001
10 92.96** p < .001
11 84.12* p = .020
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ȽǦ
ǡȽǦǤ We asked whether induced 
overexpression of α-synuclein caused a detectable electrophysiological change in the rodent visual system as 
measured via the VEP and SSVEP. We have demonstrated that a small, but signiicant increase in the latency 
of the VEP measured from the let SC of α-synuclein rats occurs 11 weeks ater injection. he result of our 
cylinder test suggests that the full impact of overexpressing α-synuclein is obtained 11 weeks ater injection of 
rAAV2/5 similar to was has been reported  by19,41. hus, changes in the VEP waveform may only appear ater full 
α-synuclein expression is obtained. his diference in VEP waveform was also present at 15 weeks where it seems 
to have developed further. his suggests that the functional consequences of overexpressing α-synuclein develop 
slower than as evidenced by the histological phenotype and might be further aggravated by downstream efects 
such as changes in α-synuclein homeostasis, phosphorylation or aggregation. he AAV-mediated expression of 
human α-synuclein was massively present in the entire substantia nigra both pars compacta and pars reticulata. 
In the rodent, the substantia nigra par reticulata (SNr) has direct projections to the  SC22. his connection may 
explain how α-synuclein immunoreactivity are detectable in the SC, as the protein is transported and expressed 
within the cells. An alternative possibility being that the observed α-synuclein in the SC originates from the 
GABAergic processes connecting the SC and the  SNc42. However, the exact mechanism by which α-synuclein 
increases the latency of the rodent VEP remains to be elucidated. Similar connections are found in humans, and 
Figure 5.  Histogram plots of classiication accuracy across 1,000 bootstrapped SVM classiications. he SVM 
is highly accurate in classifying between α-synuclein and control rats at each week, when all electrodes are 
included in the analysis. Virtually no classiication runs occurred below the 50% baseline. Plots of classiication 
accuracy ater shuling labels are included (dotted lines). Here, accuracies fell around the 50% baseline.
Table 2.  Mean SVM classiication accuracy at each timepoint ater 1,000 bootstrapped runs, comparing 
between the superior colliculus electrode ipsilateral to the injection and superior colliculus electrode 
contralateral to the injection within α-synuclein rats. **p < 0.001, *p < 0.05.
Week Accuracy (%) p-value
3 67.87* p = 0.042
5 81.46** p < 0.000
6 67.23* p = 0.047
7 77.17* p = 0.002
8 84.48* p = 0.000
9 69.52* p = 0.036
10 66.35 p = 0.062
11 73.01* p = 0.032
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so this could provide α-synuclein aggregates with a route to the SNr and SNc. In humans, α-synuclein have not 
been found in GABAergic  cells43, whereas, aggregates of α-synuclein have been identiied in the  SC44.
 ȽǦ   	 ? ? ?      Ǥ he rodent AAV 
α-synuclein model may be used as a preclinical model to monitor disease-related progression and modula-
tion by pharmacotherapy. Previous studies have found an interaction between LRRK2 function and α-synuclein 
induced  phenotypes19,45. Similar to Andersen et  al.19, we tested whether an acute dose of the LRRK2 kinase 
inhibitor PFE360 could modulate the VEP waveform. PFE360 caused an increase in the VEP latency which was 
observed for both the control and AAV-α-synuclein groups; however, treatment with PFE360 did not show any 
interaction with α-synuclein. his result does not exclude that α-synuclein and LRRK2 interact under other 
conditions or in other brain areas. PFE360 increases the general latencies of the VEP, suggesting a function for 
LRRK2 in facilitating post-synaptic potentials. Studies of the rodent brain have localised LRRK2 in the cortex 
and the  striatum46 but not in the SC. Yet the present study indicates comparable efects in both the SC and the 
VC.
     Ǥ here were general trends for changes in SSVEPs in 
α-synuclein rats, however post-hoc tests revealed that these trends were not signiicant. he SSVEP waveform 
originates from the summation of many repeated waveforms and while the temporal sensitivity and SNR are 
theoretically very high, it is possible that subtle diferences in response waveform shape (such as we ind in the 
event-related VEP) are obscured in the steady-state at the level of individual electrodes.
 ƤǤ Previously, it 
has been demonstrated that machine learning classiiers are a useful tool for establishing new visual biomark-
ers in Drosophila PD  models26,27. Here, using information from all electrodes simultaneously, our SVM could 
accurately classify α-synuclein and control rats into their correct group across difering stages of α-synuclein 
overexpression. Rats could be classiied into their correct group at all weeks with very high accuracy (84–93%). 
Second, SSVEP amplitudes from the let and right SC of α-synuclein rats were analysed using the SVM. he dif-
ferences between these two groups were purely due to the injection of the AAV carrying human α-synuclein and 
not the empty vector AAV. We were able to classify rats into their correct group at most weeks—with signiicant 
accuracies between 67 and 84%.
One might expect the highest accuracy in the second analysis, comparing SSVEPs measured from the let SC 
(where α-synuclein inclusions were localized) with responses from the right SC that did not receive the AAV-
vector and appeared structurally healthy. However, the SVM generally performed better when data from all 
electrodes were included in the classiier. One reason for this may be that SVM accuracy increases with increased 
Figure 6.  Histogram plots of classiication accuracy across 1,000 bootstrapped SVM classiications. he SVM 
was able to classify between the (treated) let superior colliculus and the (untreated) right superior colliculus 
within α-synuclein rats, except at week 10. Plots of classiication accuracy ater shuling labels are included. 
Here, accuracies fell around the 50% baseline.
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number of features; in the irst analysis 40 features were included, while the second analysis only included 10 
features. Accuracy increasing with more features suggests that these additional features were relevant to the 
classiier itself, even though these data originated from electrodes where the efect of α-synuclein overexpression 
was not observable by VEP or immunohistochemistry. his indicates nuanced but signiicant diferences in the 
SSVEP amplitudes that occur as a result of the overexpression of α-synuclein. Notably, the classiier identiied 
diferences in SSVEP response as early as three weeks ater the administration of the AAV vector and these dif-
ferences persisted across the progression of the increases of protein expression over time. Previous research has 
identiied cell-to-cell transmission and the formation of exogenous α-synuclein ibrils in animal models express-
ing mutated SNCA47. Although we did not detect any human α-synuclein in the hemisphere contralateral to the 
injection site, our data suggest that the functional efect of α-synuclein overexpression may cause changes in 
long-range neural signalling that results in perturbations of the SSVEP measured from the opposing hemisphere.
here are clear beneits in combining electrophysiological measurements of visual processes and novel clas-
siication techniques. First, it may enhance early-stage drug discovery using animal disease models. Second, the 
accuracy (or inaccuracy) of a classiier in diferentiating between visual processes recorded from a PD model 
that has been treated with a therapeutic drug against a healthy control animal allows for the objective assess-
ment of whether a treatment has rescued visual functioning (i.e. are the responses between these two classes 
now indistinguishable). Further, with evidence for visual biomarkers in a range of simple ly models of PD, and 
now a more complex rodent model, it may soon be possible to translate such methods and classify human PD 
patients into their correct genotype based on similar electrophysiological response  proiles48.

We have established that the latency of the VEP is sensitive to overexpression of α-synuclein. his efect was 
localized to the site of α-synuclein overexpression. Next, we found that the administration of the LRRK2 inhibitor 
PFE360 caused general delays in the VEP which may suggest a function for LRRK2 in facilitating post-synaptic 
potentials. hese delays were independent of the presence of human α-synuclein. Finally, we found that the 
SSVEP was sensitive to the presence of α-synuclein across multiple stages of α-synuclein overexpression and 
that such overexpression may cause changes in long-range neural signalling. hese indings highlight the utility 
of the visual system to investigate changes in neural signalling that occurs in PD models. Overall, these indings 
may prove beneicial for producing methods that assist in the early diagnosis of PD in humans and testing new 
therapeutic treatments in disease models that aim to rescue neural responses.

he extracted EEG data, can be provided upon request. he raw scans of western blot membranes can be pro-
vided upon request.
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